Microdosing of scopolamine as a "cognitive stress test": Rationale and test of a very low dose in an at-risk cohort of older adults

Alzheimer's and Dementia

Volumn 10, Issue 2, 2014, Pages 262-267

  Snyder, Peter J ^a,b   Lim, Yen Ying ^a,b   Schindler, Rachel ^c   Ott, Brian R ^a,b   Salloway, Stephen ^a,d   Daiello, Lori ^a,b   Getter, Christine ^b   Gordon, Catherine M ^a,b   Maruff, Paul ^e,f  

^a BROWN UNIVERSITY   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

^c PFIZER INC   (United States)

^d BUTLER HOSPITAL   (United States)

^e Scientific Division   (Australia)

^f UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Alzheimer disease; Anticholinergic drugs; Biomarkers; Cholinergic; Cognition; Diagnosis; Early detection; Preclinical Alzheimer's disease; Scopolamine; Amyloid protein

Indexed keywords

AMYLOID BETA PROTEIN; SCOPOLAMINE;

ADULT; AGED; ARTICLE; BODY MASS; EXERCISE TEST; FEMALE; FOLLOW UP; HUMAN; HUMAN EXPERIMENT; MALE; MIDDLE AGED; NORMAL HUMAN; PRIORITY JOURNAL; RISK FACTOR;

ALZHEIMER DISEASE; ANTICHOLINERGIC DRUGS; BIOMARKERS; CHOLINERGIC; COGNITION; DIAGNOSIS; EARLY DETECTION; PRECLINICAL ALZHEIMER'S DISEASE; SCOPOLAMINE; Β-AMYLOID PROTEIN;

AGED; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; ANILINE COMPOUNDS; CHOLINERGIC ANTAGONISTS; COGNITION DISORDERS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; EARLY DIAGNOSIS; ETHYLENE GLYCOLS; FEMALE; HUMANS; MALE; MAZE LEARNING; MIDDLE AGED; MOOD DISORDERS; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY; PSYCHIATRIC STATUS RATING SCALES; SCOPOLAMINE HYDROBROMIDE; TIME FACTORS; TOMOGRAPHY SCANNERS, X-RAY COMPUTED;

EID: 84897513537     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2014.01.009     Document Type: Article

References (30)

1. E.M. Reiman, J.B. Langbaum, and P.N. Tariot Alzheimer's Prevention Initiative: a proposal to evaluate presymptomatic treatments as quickly as possible Biomark Med 4 2010 3 14
2. P.J. Whitehouse, and K.S. Au Cholinergic receptors in aging and Alzheimer's disease Prog Neuropsychopharmacol Biol Psychiatry 10 1986 665 676
3. P.E. Potter, P.K. Rauschkolb, Y. Pandya, L.I. Sue, M.N. Sabbagh, and D.G. Walker et al. Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimer's disease Acta Neuropathol 122 2011 49 60
4. T.G. Beach, Y.M. Kuo, K. Spiegel, M.R. Emmerling, L.I. Sue, and Kokjohn K et al. The cholinergic deficit coincides with Abeta deposition at the earliest histopathologic stages of Alzheimer disease J Neuropathol Exp Neurol 59 2000 308 313
5. T.G. Beach, W.G. Honer, and L.H. Hughes Cholinergic fibre loss associated with diffuse plaques in the non-demented elderly: the preclinical stage of Alzheimer's disease? Acta Neuropathol 93 1997 146 153
6. E.J. Mufson, S.E. Counts, M. Fahnestock, and S.D. Ginsberg Cholinotrophic molecular substrates of mild cognitive impairment in the elderly Curr Alzheimer Res 4 2007 340 350
7. A.E. Roher, Y.M. Kuo, P.E. Potter, M.R. Emmerling, R.A. Durham, and D.G. Walker et al. Cortical cholinergic denervation elicits vascular A beta deposition Ann N Y Acad Sci 903 2000 366 373
8. J.A. Araujo, J.N. Nobrega, R. Raymond, and N.W. Milgram Aged dogs demonstrate both increased sensitivity to scopolamine impairment and decreased muscarinic receptor density Pharmacol Biochem Behav 98 2011 203 209
9. C.M. Stonnington, P.J. Snyder, J.G. Hentz, E.M. Reiman, and R.J. Caselli Double-blind crossover study of the cognitive effects of lorazepam in healthy apolipoprotein E (APOE)-epsilon4 carriers J Clin Psychiatry 70 2009 1379 1384
10. P.W. Schofield, H. Ebrahimi, A.L. Jones, G.A. Bateman, and S.R. Murray An olfactory 'stress test' may detect preclinical Alzheimer's disease BMC Neurol 12 2012 1 8
11. K.K. Wong, M.T. Ho, H.Q. Lin, K.F. Lau, J.A. Rudd, and R.C. Chung et al. Cryptotanshinone, an acetylcholinesterase inhibitor from Salvia miltiorrhiza, ameliorates scopolamine-induced amnesia in Morris water maze task Planta Med 76 2010 228 234
12. S.H. Kwon, H.K. Lee, J.A. Kim, S.I. Hong, H.C. Kim, and T.H. Jo et al. Neuroprotective effects of chlorogenic acid on scopolamine-induced amnesia via anti-acetylcholinesterase and anti-oxidative activities in mice Eur J Pharmacol 649 2010 210 217
13. P. Snyder, M.M. Bednar, J.R. Cromer, and P. Maruff Reversal of scopolamine-induced deficits with a single dose of donepezil, an acetylcholinesterase inhibitor Alzheimers Dement 1 2005 126 135
14. R.A. Lenz, J.D. Baker, C. Locke, L.E. Rueter, E.G. Mohler, and K. Wesnes et al. The scopolamine model as a pharmacodynamic marker in early drug development Psychopharmacology (Berl) 220 2012 97 107
15. T. Sunderland, P.N. Tariot, R.M. Cohen, H. Weingartner, E.A. Mueller 3rd, and D.L. Murphy Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. A dose-response study Arch Gen Psychiatry 44 1987 418 426
16. S.E. Molchan, R.A. Martinez, J.L. Hill, H.J. Weingartner, K. Thompson, and B. Vitiello et al. Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model Brain Res Brain Res Rev 17 1992 215 226
17. K. Wesnes, P. Simpson, and A. Kidd An investigation of the range of cognitive impairments induced by scopolamine 0.6mg s.c Human Psychopharmacol 3 1988 27 41
18. A. Fredrickson, P.J. Snyder, J. Cromer, E. Thomas, M. Lewis, and P. Maruff The use of effect sizes to characterize the nature of cognitive change in psychopharmacological studies: an example with scopolamine Human Psychopharmacol 23 2008 425 436
19. S.A. Roman, J.A. Sosa, R.H. Pietrzak, P.J. Snyder, D.C. Thomas, and D.C. Thomas et al. The effects of serum calcium and parathyroid hormone changes on psychiatric and cognitive function in patients undergoing parathyroidectomy for primary hyperparathyroidism Ann Surgery 253 2011 131 137
20. P.J. Snyder, J. Werth, B. Giordani, A.F. Caveney, D. Feltner, and P. Maruff A method for determining the magnitude of change across different cognitive functions in clinical trials: the effects of acute administration of two different doses alprazolam Human Psychopharmacol 20 2005 263 273
21. J. Ingrande, and H.J. Lemmens Dose adjustment of anaesthetics in the morbidly obese Br J Anaesth 105 2010 16 23
22. L.E.C. De Baerdemaeker, E.P. Mortier, and M.M.R.F. Struys Pharmacokinetics in obese patients. Continuing education in anaesthesia Crit Care Pain 4 2004 152 155
23. T.H. Crook, E.P. Feher, and G.J. Larrabee Assessment of memory complaint in age-associated memory impairment: the MAC-Q Intl Psychogeriatr 4 1992 165 176
24. MIMneuro User Guide Version 6.1 2013 MIM Software Inc. Cleveland, OH
25. C.M. Clark, J.A. Schneider, B.J. Bedell, T.G. Beach, W.B. Bilker, and M.A. Mintun et al. Use of florbetapir-PET for imaging beta-amyloid pathology J Am Med Assoc 305 2011 275 283
26. M. Grothe, L. Zaborszky, M. Atienza, E. Gil-Neciga, R. Rodriguez-Romero, and S.J. Teipel et al. Reduction of basal forebrain cholinergic system parallels cognitive impairment in patients at high risk of developing Alzheimer's disease Cereb Cortex 20 2010 1685 1695
27. C. Flicker, R.L. Dean, D.L. Watkins, S.K. Fisher, and R.T. Bartus Behavioral and neurochemical effects following neurotoxic lesions of a major cholinergic input to the cerebral cortex of the rat Pharmacol Biochem Behavior 18 1983 973 981
28. R.A. Sperling, P.S. Aisen, L.A. Beckett, D.A. Bennett, S. Craft, and A.M. Fagan et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association workgroup Alzheimer's Dementia 7 2011 280 292
29. V.L. Villemagne, S. Burnham, P. Bourgeat, B. Brown, K.A. Ellis, and O. Salvado et al. Amyloid β deposition, neurodegeneration and cognitive decline in sporadic Alzheimer's disease: A prospective cohort study Lancet Neurol 12 2013 357 367
30. R. Schliebs, and T. Arendt The cholinergic system in aging and neuronal degeneration Behav Brain Res 221 2011 555 563